|Articles|April 10, 2018
Shanghai HEP Pharma Signs Agreement with OmniComm Systems
Advertisement
Shanghai HEP Pharma Co. has signed a new agreement with OmniComm Systems, Inc which will officially name them as TrialMaster's first customer in China. Under this agreement, Shanghai HEP Pharma will use OmniComm's TrialMaster EDC to conduct a hepatitis B study.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Applied Clinical Trials' 2025 State of the Industry Survey
2
Do Phase II Protocol Learnings Help Simplify Phase III Protocol Designs?
3
Beyond the Comment Section: Rebuilding Trust in Vaccines Through Conversation
4
ACT Brief Weekly Recap: Clinical Research Faces Funding Strain, Data Evolution, and a Shift in Outsourcing Models
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
